Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

Min Kyong Moon, Kyu Yeon Hur, Seung Hyun Ko, Seok O. Park, Byung Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan Hee Kim

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient’s clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

Original languageEnglish
Pages (from-to)974-983
Number of pages10
JournalKorean Journal of Internal Medicine
Volume32
Issue number6
DOIs
Publication statusPublished - 2017 Nov

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Metformin
Practice Guidelines
Hypoglycemia
Meta-Analysis
Body Weight
Guidelines
Therapeutics
Safety
Patient Preference
Comorbidity
Clinical Trials
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Moon, Min Kyong ; Hur, Kyu Yeon ; Ko, Seung Hyun ; Park, Seok O. ; Lee, Byung Wan ; Kim, Jin Hwa ; Rhee, Sang Youl ; Kim, Hyun Jin ; Choi, Kyung Mook ; Kim, Nan Hee. / Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. In: Korean Journal of Internal Medicine. 2017 ; Vol. 32, No. 6. pp. 974-983.
@article{8b2e8ce8bc2244d3aad235118653498a,
title = "Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus",
abstract = "The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient’s clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.",
author = "Moon, {Min Kyong} and Hur, {Kyu Yeon} and Ko, {Seung Hyun} and Park, {Seok O.} and Lee, {Byung Wan} and Kim, {Jin Hwa} and Rhee, {Sang Youl} and Kim, {Hyun Jin} and Choi, {Kyung Mook} and Kim, {Nan Hee}",
year = "2017",
month = "11",
doi = "10.3904/kjim.2017.354",
language = "English",
volume = "32",
pages = "974--983",
journal = "Korean Journal of Internal Medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "6",

}

Moon, MK, Hur, KY, Ko, SH, Park, SO, Lee, BW, Kim, JH, Rhee, SY, Kim, HJ, Choi, KM & Kim, NH 2017, 'Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus', Korean Journal of Internal Medicine, vol. 32, no. 6, pp. 974-983. https://doi.org/10.3904/kjim.2017.354

Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. / Moon, Min Kyong; Hur, Kyu Yeon; Ko, Seung Hyun; Park, Seok O.; Lee, Byung Wan; Kim, Jin Hwa; Rhee, Sang Youl; Kim, Hyun Jin; Choi, Kyung Mook; Kim, Nan Hee.

In: Korean Journal of Internal Medicine, Vol. 32, No. 6, 11.2017, p. 974-983.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

AU - Moon, Min Kyong

AU - Hur, Kyu Yeon

AU - Ko, Seung Hyun

AU - Park, Seok O.

AU - Lee, Byung Wan

AU - Kim, Jin Hwa

AU - Rhee, Sang Youl

AU - Kim, Hyun Jin

AU - Choi, Kyung Mook

AU - Kim, Nan Hee

PY - 2017/11

Y1 - 2017/11

N2 - The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient’s clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

AB - The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient’s clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

UR - http://www.scopus.com/inward/record.url?scp=85034588405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034588405&partnerID=8YFLogxK

U2 - 10.3904/kjim.2017.354

DO - 10.3904/kjim.2017.354

M3 - Review article

C2 - 29096431

AN - SCOPUS:85034588405

VL - 32

SP - 974

EP - 983

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 1226-3303

IS - 6

ER -